Search

In collaboration with Julius Clinical, TRICALS will present the webinar: “Efficient Patient Identification in ALS Clinical Trials; Leveraging the Concept of Fast and Slow Progressors”. The webinar will take place on November 10, 2020 at 18:00 CET.

This phase 3 trial, which is sponsored by Alexion Pharmaceuticals, aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. The study intends to recruit 354 adults with either sporadic or familial ALS.

A new law has been passed in the United States to give more people with ALS access to experimental treatments. The government is also pledging $100 million a year for research into new treatments over the next five years.

Two weeks ago, we presented the free webinar: “Efficient Patient Identification in ALS Clinical Trials; Leveraging the Concept of Fast and Slow Progressors.” This was done in collaboration with Julius Clinical. Over 70 people registered to attend the webinar and we would like to thank everyone for their interest. We...

Tuesday December 8th at 15.30-17.30 CET, ENCALS and TRICALS will be sharing their latest updates in the online ‘ENCALS Satellite Meeting 2020’. This satellite meeting is prior to the 31st International Symposium on ALS/MND on 9-11 December 2020 (organised by the MND Association). The goal of this satellite meeting i...

In the run-up to the virtual 31st International Symposium on ALS/MND, the ENCALS Satellite meeting was held online this year. The goal of this meeting is to discuss international collaborations, SOPs and translation of new developments to the clinic. Nearly 200 people attended this year.

Last week the 31st International Symposium on ALS/MND was held online. This is the largest medical and scientific conference for ALS/MND experts and takes place every year. Below we provide a brief summary of our highlights for this year.

Questionnaires, such as the ALS Functional Rating Scale (ALSFRS), play an important role in ALS clinical trials. They are used to evaluate whether treatments have an effect on functional decline. However, if questions are not selected appropriately, they can miss important treatment effects. 20 years ago, the ALSFRS...

This year, ENCALS (European Network to Cure ALS) will be organising their annual meeting online. The meeting will take place on 12-14 May. Registration and abstract submission are now open.

Retrotope Inc has announced that the first participants have been enrolled in their new phase 2 clinical trial. This trial evaluates the safety and efficacy of the compound RT001 in people living with ALS. The study intends to recruit 40 participants living from different countries. Retrotope expects the study to en...

Today, Amylyx Pharmaceuticals provided an update on its plans to advance its oral compound ‘AMX0035’ through the clinical development process for the treatment of ALS. They have announced that they will submit a Marketing Authorisation Application to the European Medicines Agency (EMA). In addition, following promis...

Due to a new study design for clinical trials, more ALS patients are eligible to participate. This has been shown by recent research. Selecting patients differently and adapting the trial design, results in several benefits for both patient and researcher.